Macquarie Group Ltd. Has $33.19 Million Stake in The Medicines Company (MDCO)
Macquarie Group Ltd. raised its holdings in shares of The Medicines Company (NASDAQ:MDCO) by 44.4% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 873,182 shares of the company’s stock after acquiring an additional 268,282 shares during the quarter. Macquarie Group Ltd. owned approximately 1.20% of The Medicines worth $33,190,000 as of its most recent filing with the SEC.
Several other large investors have also added to or reduced their stakes in the company. Municipal Employees Retirement System of Michigan boosted its position in shares of The Medicines by 0.3% during the 1st quarter. Municipal Employees Retirement System of Michigan now owns 15,850 shares of the company’s stock worth $775,000 after acquiring an additional 50 shares in the last quarter. US Bancorp DE boosted its position in shares of The Medicines by 1.7% in the 1st quarter. US Bancorp DE now owns 3,413 shares of the company’s stock valued at $167,000 after purchasing an additional 58 shares during the period. First Mercantile Trust Co. boosted its position in shares of The Medicines by 2.5% in the 2nd quarter. First Mercantile Trust Co. now owns 4,767 shares of the company’s stock valued at $181,000 after purchasing an additional 114 shares during the period. Envestnet Asset Management Inc. boosted its position in shares of The Medicines by 5.1% in the 1st quarter. Envestnet Asset Management Inc. now owns 2,496 shares of the company’s stock valued at $122,000 after purchasing an additional 120 shares during the period. Finally, State Board of Administration of Florida Retirement System boosted its position in shares of The Medicines by 0.6% in the 2nd quarter. State Board of Administration of Florida Retirement System now owns 39,599 shares of the company’s stock valued at $1,505,000 after purchasing an additional 219 shares during the period.
The Medicines Company (NASDAQ:MDCO) traded up 0.21% during mid-day trading on Monday, reaching $38.25. The company’s stock had a trading volume of 32,846 shares. The firm has a 50-day moving average of $36.21 and a 200-day moving average of $41.20. The stock’s market capitalization is $2.75 billion. The Medicines Company has a 52 week low of $30.80 and a 52 week high of $55.95.
The Medicines (NASDAQ:MDCO) last issued its earnings results on Wednesday, August 9th. The company reported ($5.52) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.29) by ($4.23). The Medicines had a negative net margin of 670.46% and a negative return on equity of 137.20%. The company had revenue of $18.74 million during the quarter, compared to analyst estimates of $29.64 million. During the same quarter in the previous year, the firm earned ($0.62) earnings per share. The business’s revenue was down 65.8% on a year-over-year basis. On average, equities research analysts expect that The Medicines Company will post ($9.69) earnings per share for the current year.
A number of analysts recently issued reports on the company. Zacks Investment Research raised The Medicines from a “hold” rating to a “buy” rating and set a $41.00 target price for the company in a research report on Tuesday, August 8th. Citigroup Inc. decreased their target price on The Medicines from $59.00 to $43.00 and set a “neutral” rating for the company in a research report on Monday, July 17th. Chardan Capital reissued a “buy” rating and issued a $85.00 target price on shares of The Medicines in a research report on Wednesday, September 20th. Jefferies Group LLC reissued a “buy” rating and issued a $62.00 target price on shares of The Medicines in a research report on Wednesday, June 28th. Finally, Oppenheimer Holdings, Inc. set a $50.00 target price on The Medicines and gave the company a “hold” rating in a research report on Thursday, August 17th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $54.00.
ILLEGAL ACTIVITY NOTICE: “Macquarie Group Ltd. Has $33.19 Million Stake in The Medicines Company (MDCO)” was published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright laws. The original version of this piece of content can be viewed at https://www.watchlistnews.com/macquarie-group-ltd-has-33-19-million-stake-in-the-medicines-company-mdco/1619668.html.
The Medicines Profile
The Medicines Company is a global biopharmaceutical company. The Company is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital marketplace around the world. It markets Angiomax (bivalirudin), Ionsys (fentanyl iontophoretic transdermal system), Minocin (minocycline) for injection and Orbactiv (oritavancin).
Receive News & Ratings for The Medicines Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Medicines Company and related companies with Analyst Ratings Network's FREE daily email newsletter.